Mycept-s 360mg Tablet (Mycophenolate Sodium)
Prescription RequiredManufactured By
Panacea Biotec LTD
Pack Of
60
Salt Composition
Mycophenolate Sodium
Storage
Keep in cold place
Overview
Mycept-S 360mg Delayed-Release Tablet contains Mycophenolate Sodium as an active ingredient. It is classified as one of the antimetabolite immunosuppressants. Therefore, Mycophenolate Sodium tablet is taken along with other immunosuppressive agents for preventing rejection of the graft following transplantation of a kidney.
Mycept-S 360 Tablet acts by decreasing the activity and proliferation of specific immune cells which could attack the kidney graft. However, the Mycept-S 360 Tablet is an enteric-coated extended-release tablet. It must be swallowed as such without crushing, splitting or chewing. This is significant because the mycophenolic acid extended-release tablets cannot be exchanged with mycophenolate mofetil in equal mg doses.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Brand | mycept-s |
| Generic / Active Ingredient | Mycept-s |
| Strength | 360 |
| Dosage Form | Tablet |
| Manufacturer / Marketer | Panacea Biotec LTD |
| Pack Size | 60 |
| Prescription Required | Yes |
| Therapeutic Categories | Cancer Medicines |
| Uses | kidney cancer |
Uses and Indications
Mycept-S 360mg Tablet is used for:
Preventing rejection of kidney transplant
Mycophenolate Sodium 360mg tablet is usually recommended for a combination therapy which normally involves the use of cyclosporine and corticosteroids. This drug decreases the activity of the immune system, thereby lowering the chances of the immune system rejecting the newly transplanted organ.
How Mycept-s 360mg Tablet Works
The active substance of Mycept-S 360mg tablet is mycophenolate sodium, which acts in the form of mycophenolic acid. Mycophenolic acid inhibits the activity of the enzyme inosine monophosphate dehydrogenase (IMPDH), thus decreasing the synthesis of components necessary for the multiplication of immune cells. This inhibits the proliferation of activated T and B lymphocytes, thereby weakening the immune response leading to rejection of the graft.
Clinical Evidence for Mycept-s 360mg Tablet
- Delayed-release tablets containing mycophenolic acid have undergone testing within the context of immunosuppressive combination therapy in kidney transplant recipients. Treatment outcomes are linked to the entire regimen applied and depend on the immunosuppressive drugs administered alongside mycophenolic acid.
- The findings concern delayed-release treatment with mycophenolic acid and must not be taken as evidence for Mycept-S 30mg.
Side Effects of Mycept-s 360mg Tablet
Some patients can have:
- Diarrhea
- Nausea
- Constipation
- Anemia
- Low white blood cells
- Infection
Not all patients will get these side effects. It is important to inform your healthcare provider about any ongoing or bothersome side effects.
Critical Safety Warning
Mycophenolate sodium 360mg tablet decreases the activity of the immune system in order to prevent organ transplantation rejection; however, it is linked to some health concerns due to its immunosuppressive effects. Among other safety issues that should be considered are:
- Serious infections: Immunosuppression can lead to increased risks of infections.
- Specific malignancies: Risks of developing lymphoma and skin cancer can be increased.
- Disorders of blood cells: There can be changes in blood cell counts during treatment.
- Gastrointestinal complications: Bleeding, ulcers, and perforations can occur.
- Viral infections: Some viruses can become active or develop as well.
- Pregnancy: Mycophenolate sodium tablet can induce miscarriages and congenital malformations. Pregnancy testing and contraception should be done properly.
- Vaccination: Live attenuated vaccines are usually contraindicated during treatment.
Mycept-s 360mg Tablet Dosage and How To Take It
| Clinical situation | Dose |
|---|---|
| Unit strength | 360mg mycophenolic acid equivalent per tablet |
| Administration | Swallow whole with water |
| Route | Oral |
| Dose changes | Only on the treating clinician’s instructions. |
Mycept-s 360mg Tablet Missed Dose
In case you miss a dose, it is advised that you inform your transplant team or follow the instructions given on the medication. Never double a dose to compensate for the missed one without the instruction from your healthcare provider.
Safety Advice for Mycept-s 360mg Tablet
| Category | Status | Guidance |
|---|---|---|
| Pregnancy | High Risk | Specialist assessment is required as Mycophenolate sodium 360mg is strongly embryo-fetotoxic. |
| Breastfeeding | Requires Specialist Advice | Discuss with the treating specialist before breastfeeding. |
| Kidney function | Regular Monitoring | Function of the kidney should also be checked during the follow-up after transplantation. |
| Liver function | As Clinically Indicated | Checking can be done if and when required. |
| Infections | Increased Risk | Inform about any fever, continuous cough, abnormal weakness, or any other symptoms related to infection. |
| Vaccines | Requires Specialist Guidance | Live vaccination must be avoided unless specifically recommended by the transplant team. |
| Self- adjustment | Not Recommended | Never discontinue, decrease or modify the dose of Mycophenolate sodium 360mg without proper guidance. |
Monitoring During Mycept-s 360mg Tablet Treatment
Regular follow-up is necessary while being on Mycept-S 360mg treatment and may involve the following procedures:
- Complete blood count (CBC) for anemia and abnormality in the number of white blood cells.
- Renal function tests in the context of transplantation procedure.
- Liver function tests if needed.
- Indicators of infection, which may be bacterial, viral, fungal, or opportunistic infections.
- Functionality of the graft.
- Screening for pregnancy and contraception methods if needed.
- Viral monitoring if needed.
Mycept-s 360mg Tablet Fact Box
| Parameter | Verified / publication wording |
|---|---|
| Molecule | Mycophenolate sodium |
| Strength | 360mg mycophenolic acid equivalent per tablet |
| Dosage form | Enteric-coated delayed-release oral tablet |
| Class | Antimetabolite immunosuppressant |
| Uses | Prevention of kidney-transplant rejection |
| How to take | Usually on an empty stomach, 1 hour before or 2 hours after food |
| Key warning | Loss of pregnancy and congenital malformations; severe infection; blood problems; risk for cancer; gastrointestinal problems |
Mycept-s 360mg Tablet Drug Interactions
| Drug / Class | Risk | What To Do |
|---|---|---|
| Magnesium/Aluminium-containing Antacids | Decreased exposure to mycophenolic acid | Check the administration time with the healthcare provider. |
| Cholestyramine | Reduced mycophenolic acid exposure | Avoid or use under supervision of the healthcare professional. |
| Certain Antiviral Medicines | Altered exposure to mycophenolic acid or increased side effects | Review combination and follow advice of the healthcare expert. |
| Live Vaccines | Decreased efficacy of vaccines and increased susceptibility to infections | Not advisable unless prescribed by your transplant team. |
| Other Immunosuppressants | Higher levels of immunosuppression or toxicity | Can be used only with professional oversight. |
FAQs About Mycept-s 360mg Tablet
What is Mycept-S 360 mg Tablet?
Mycept-S 360 mg is an oral delayed release tablet which contains mycophenolate sodium, which is equal to 360 mg of mycophenolic acid per tablet.
What is Mycophenolate sodium tablet for?
Mycept-S 360 mg is used along with other drugs that suppress immunity to prevent kidney transplantation rejection.
How does Mycept-S 360mg tablet work?
Mycophenolate sodium tablet inhibits the formation of substances that are required for activated immune cells to proliferate.
What is the typical adult dosage Of Mycept-S 360 mg Tablet?
The recommended kidney transplant dose of Mycept-S 360 mg for adults is 720mg to be taken twice a day for a total of 1,440mg.
Is Mycept-S Tablet administered with food?
Mycophenolate sodium 360mg tablet is normally taken on an empty stomach, either 1 hour before meals or 2 hours after food intake. Please refer to the guidelines from your transplant team.
Are Mycept-S tablet chewable?
No. It should not be chewed, opened, or broken, however, discuss with the doctor for correct dosage of the medicine.
Is there any way to substitute Mycept-S 360mg tablet with mycophenolate mofetil?
Only with medical consent. Mycophenolate Sodium tablet and mycophenolate mofetil possess different absorption properties, so it is important to make the replacement only under doctor’s recommendation.
Which side effects are typical for mycophenolate mofetil?
Typical effects may be as follows: diarrhea, nausea, constipation, anemia, low white blood cells and infections.
What are the major warning signs during the treatment?
Important adverse reactions are pregnancy complications, birth defects, serious infections, blood cell abnormalities, increased risk of developing cancer, and significant gastrointestinal reactions.
Which kind of monitoring is required while using Mycophenolate Sodium 360mg tablet?
Blood tests, renal function testing, laboratory tests (when required), monitoring of graft function, infection screening, and pregnancy testing are all necessary while using this drug.
Is it possible to discontinue the use of Mycept-S 360mg tablet when feeling good?
No, it is not. Discontinuation or dose change of the medication can provoke organ rejection.
References
- DailyMed. Mycophenolic Acid Delayed-Release Tablets – Prescribing Information. U.S. National Library of Medicine https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7c05bf9-816f-41e6-999d-bb3c7abd2627
- U.S. Food and Drug Administration (FDA). MYFORTIC (mycophenolic acid) Delayed-Release Tablets – Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050791s019lbl.pdf
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients https://pubmed.ncbi.nlm.nih.gov/19845597/
- European Medicines Agency (EMA). Myfortic – EPAR / Product Informationhttps://www.ema.europa.eu/en/medicines/human/EPAR/mycophenolate-mofetil-teva
- U.S. National Library of Medicine. Mycophenolic Acid – MedlinePlus Drug Information https://medlineplus.gov/druginfo/meds/a601081.html
Marketer Details
Panacea Biotec LTD
Author Details
Written By:
Nonish Sharma
I am a medical content writer with a strong academic background in life sciences, holding an M.Sc. in Biotechnology... Read More
Reviewed By:
Vaibhav Shakya
Dr. Vaibhav Shakya, MD, is a Medical reviewer and medicine expert at Globans Pharma, with more than 9 years of experienc... Read More
Want to know More
Check our Editor Policy
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.
